Atlantic Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Atlantic Biotech's estimated annual revenue is currently $2.3M per year.
- Atlantic Biotech's estimated revenue per employee is $155,000
Employee Data
- Atlantic Biotech has 15 Employees.
- Atlantic Biotech grew their employee count by 0% last year.
Atlantic Biotech's People
Name | Title | Email/Phone |
---|
Atlantic Biotech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Atlantic Biotech?
At Atlantic Biotech, we are committed to providing our clients with fast, accurate and cost-efficient toxicology testing services that help enhance patient care to its greatest potential. We have invested in the best state-of-the-art testing facilities and equipment so that we can provide the utmost level of test-result precision available. Our results use some of the lowest analytical cutoff rates in the industry, and we are one of only a few lab companies nationwide that utilizes a seven-drug adulteration test to validate specimen integrity. Not only do we ensure that results are easy to read and interpret, but we also use innovative confirmation-test software that provides explanations for positive results, including possible drug crossover. We know Lives are on the line!
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.6M | 15 | -12% | N/A |
#2 | $1.5M | 17 | 6% | N/A |
#3 | $1.5M | 17 | 6% | N/A |
#4 | $1.5M | 17 | 6% | N/A |
#5 | $3.1M | 18 | -80% | N/A |